Bridge Therapeutics, Inc. is a development-stage pharmaceutical company pursuing FDA approval of BT 219, a better delivery of buprenorphine-naloxone for opioid use disorder (OUD), and approval of BT-205, a patented drug combination for the treatment of chronic pain in opioid-experienced patients (U.S. Patent #8410092).
To improve the healthcare of millions of patients through safer and more effective therapies for opioid use disorder (OUD) and chronic pain.
“OUD patients should welcome BT-219’s superior delivery of buprenorphine-naloxone.“
“Chronic pain patients should transition from standard opioid therapy to BT-205 without withdrawal and without euphoria, which is the main reason for abusing pain killers.“
DR. GREG SULLIVAN